A detailed history of Susquehanna International Group, LLP transactions in Beyond Spring Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 17,700 shares of BYSI stock, worth $43,365. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,700
Previous 134,900 86.88%
Holding current value
$43,365
Previous $121,000 47.93%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.06 - $1.81 $82,297 - $140,526
-77,639 Reduced 74.96%
25,939 $26,000
Q2 2022

Aug 15, 2022

BUY
$1.13 - $2.66 $85,371 - $200,963
75,550 Added 269.55%
103,578 $149,000
Q1 2022

May 16, 2022

SELL
$1.68 - $5.01 $121,511 - $362,363
-72,328 Reduced 72.07%
28,028 $62,000
Q4 2021

Feb 14, 2022

SELL
$4.02 - $16.84 $597,275 - $2.5 Million
-148,576 Reduced 59.69%
100,356 $455,000
Q3 2021

Nov 15, 2021

BUY
$9.26 - $31.31 $1.63 Million - $5.5 Million
175,617 Added 239.54%
248,932 $3.92 Million
Q2 2021

Aug 11, 2021

SELL
$9.37 - $12.12 $61,364 - $79,373
-6,549 Reduced 8.2%
73,315 $765,000
Q1 2021

May 17, 2021

BUY
$10.61 - $15.77 $689,692 - $1.03 Million
65,004 Added 437.44%
79,864 $884,000
Q4 2020

Feb 16, 2021

BUY
$10.21 - $17.31 $151,720 - $257,226
14,860 New
14,860 $181,000
Q4 2019

Feb 14, 2020

SELL
$11.83 - $18.68 $129,562 - $204,583
-10,952 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$15.33 - $23.85 $167,894 - $261,205
10,952 New
10,952 $198,000
Q2 2018

Aug 14, 2018

SELL
$26.29 - $33.0 $251,726 - $315,975
-9,575 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$20.39 - $33.94 $195,234 - $324,975
9,575 New
9,575 $245,000

Others Institutions Holding BYSI

About BeyondSpring Inc.


  • Ticker BYSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,928,900
  • Market Cap $95.4M
  • Description
  • BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...
More about BYSI
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.